These data indicate that NLRP3 binds to il-4 promoter sequences and controls IL-4 levels in malignant CD4+ T cells from early CTCL lesions. This evidence concerns the gene NLRP3 and primary cutaneous T-cell non-Hodgkin lymphoma.